Market Access News | pharmaphorum

News

Equity_World_Access_Map_1140x675_CountryList

Pfizer makes non-profit pledge for low-income nations

US pharma giant Pfizer has said it will sell some of its patented medicines at non-profit prices to 45 of the world's poorest countries – including new launches.

News

Dermavant claims its first approval as FDA clears psoriasis ...

Roivant group company Dermavant has made the transition to a commercial-stage company after getting FDA approval for Vtama, a drug for psoriasis that it claims could be a game-changer in th

News

NICE finds solution to making Keytruda available for TNBC

Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other parts of the body could soon access treatment with Merck & Co/MSD's Keytruda,

News

Third FDA rejection for Verrica's molluscum contagiosum drug

Shares in US biotech Verrica Pharma lost half their value today after the FDA declined to approve its candidate treatment for viral skin infection molluscum contagiosum for a third time.

News

Angle claims FDA okay for Parsortix liquid biopsy system

After more than six years of development, Angle has scored an FDA approval for Parsortix as a diagnostic for metastatic breast cancer – the first ever in the US for a device used to detect

News

Nymox slumps as FDA rejects filing for prostate drug

Shares in US biotech Nymox Pharma have plunged after the company announced the FDA had refused to accept its marketing application for its drug candidate for benign prostatic hyperplasia (B

Pfizer makes non-profit pledge for low-income nations

Dermavant claims its first approval as FDA clears psoriasis ...

NICE finds solution to making Keytruda available for TNBC

Third FDA rejection for Verrica's molluscum contagiosum drug

Angle claims FDA okay for Parsortix liquid biopsy system

Nymox slumps as FDA rejects filing for prostate drug

FDA starts review of Regeneron's drug for rare disease FOP

How to meet your physicians where they are online

News

Editor's Picks